<DOC>
	<DOCNO>NCT02390609</DOCNO>
	<brief_summary>The purpose study assess relative bioavailability ( extent drug substance become available body ) ibrutinib healthy adult follow single oral dose administration suspension sprinkle formulation feed fast condition compare capsule fast condition .</brief_summary>
	<brief_title>A Crossover Study Evaluate Bioavailability Ibrutinib Suspension Sprinkle Formulations Compared Capsules Healthy Adults</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , randomize ( study medication assign participant chance ) , 3- 4-way crossover ( participant may receive different intervention sequentially trial ) , single-center study ibrutinib . The duration study approximately 67 83 day per participant . The study consist 3 part : Screening ( 28 day study commences Day 1 ) ; Open-label Treatment ( consist 6 treatment , either Ibrutinib capsule suspension sprinkle capsule granule fed fast condition ) , subsequent 3 period Group 1 4 period Group 2 , separate washout period 7 ( plus [ + ] / minus [ - ] 2 ) day ; follow Phase ( 10 + / - 2 day last study drug administration ) . All eligible participant randomly assign 1 6 ( Group 1 ) 4 ( Group 2 ) treatment sequence . In fasted condition , study drug administer follow 10-hour overnight fast . In fed condition , participant also fast food 10 hour , consume high fat breakfast within 30-minute period . Study drug administer 2 hour breakfast . Participants allow food 4 hour drug administration . Blood sample collect evaluation pharmacokinetics pre-dose post-dose study treatment . Relative bioavailability Ibrutinib evaluate primarily . Participants ' safety monitor throughout study .</detailed_description>
	<criteria>Signed informed consent document indicate understand purpose procedure require study willing participate study If woman , must childbearing potential : postmenopausal ( great [ &gt; ] 45 year age amenorrhea least 2 year , age amenorrhea least 6 month serum follicle stimulate hormone ( FSH ) &gt; 40 International unit [ IU ] / Liter [ L ] ) ; surgically sterile If woman , must negative serum Î²human chorionic gonadotropin ( hCG ) pregnancy test Screening negative urine pregnancy test Day1 treatment period If man sexually active woman childbearing potential vasectomy , must agree use adequate contraception method deem appropriate investigator ( eg , vasectomy , doublebarrier , partner use effective contraception ) donate sperm study 3 month receive last dose study drug Body mass index ( BMI ; weight [ kg ] /height^2 [ ] ^2 ) 18 30 Kilogram ( kg ) / meter^2 ( m^2 ) ( inclusive ) , body weight less 50 kg History current clinically significant medical illness include ( limited ) cardiac arrhythmia cardiac disease , hematologic disease , coagulation disorder ( include abnormal bleeding blood dyscrasia ) , lipid abnormality , significant pulmonary disease , include bronchospastic respiratory disease , diabetes mellitus , hepatic renal insufficiency ( creatinine clearance 60 milliliter [ mL ] / minute [ min ] ) , thyroid disease , neurologic psychiatric disease , infection , illness investigator considers exclude participant could interfere interpretation study result Clinically significant abnormal value hematology , coagulation , clinical chemistry , Screening deem appropriate investigator Clinically significant abnormal physical examination , vital sign , 12 lead electrocardiogram ( ECG ) Screening deem appropriate investigator Use prescription nonprescription medication ( include vitamin herbal supplement ) , except paracetamol hormonal replacement therapy within 14 day first dose study drug schedule completion study History drug alcohol abuse accord Diagnostic Statistical Manual Mental Disorders ( 4th edition ) ( DSMIV ) criterion within 2 year Screening positive test result ( ) alcohol and/or drug abuse ( barbiturate , opiate , cocaine , cannabinoids , amphetamine , benzodiazepine ) Screening Day1 treatment period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Ibrutinib</keyword>
	<keyword>Bioavailability</keyword>
</DOC>